Erfonrilimab

DB17446InvestigationalProtein Based Therapies

Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death 1 ligand 1
Curator reviewed
Code names: KN-046

Resolves to

Compound

UNII9NP50O6YSACAS2367013-69-0

Targets

P16410CTLA4Q9NZQ7CD274

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

27Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Erfonrilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account